{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:58:06Z","timestamp":1783123086425,"version":"3.54.6"},"reference-count":172,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Ranked high in worldwide growing health issues, pleural diseases affect approximately one million people globally per year and are often correlated with a poor prognosis. Among these pleural diseases, malignant pleural mesothelioma (PM), a neoplastic disease mainly due to asbestos exposure, still remains a diagnostic challenge. Timely diagnosis is imperative to define the most suitable therapeutic approach for the patient, but the choice of diagnostic modalities depends on operator experience and local facilities while bearing in mind the yield of each diagnostic procedure. Since the analysis of pleural fluid cytology is not sufficient in differentiating historical features in PM, histopathological and morphological features obtained via tissue biopsies are fundamental. The quality of biopsy samples is crucial and often requires highly qualified expertise. Since adequate tissue biopsy is essential, medical or video-assisted thoracoscopy (MT or VATS) is proposed as the most suitable approach, with the former being a physician-led procedure. Indeed, MT is the diagnostic gold standard for malignant pleural pathologies. Moreover, this medical or surgical approach can allow diagnostic and therapeutic procedures: it provides the possibility of video-assisted biopsies, the drainage of high volumes of pleural fluid and the administration of sterile calibrated talcum powder under visual control in order to achieve pleurodesis, placement of indwelling pleural catheters if required and in a near future potential intrapleural therapy. In this context, dedicated diagnostic pathways remain a crucial need, especially to quickly and properly diagnose PM. Lastly, the interdisciplinary approach and multidisciplinary collaboration should always be implemented in order to direct the patient to the best customised diagnostic and therapeutic pathway. At the present time, the diagnosis of PM remains an unsolved problem despite MDT (multidisciplinary team) meetings, mainly because of the lack of standardised diagnostic work-up. This review aims to provide an overview of diagnostic procedures in order to propose a clear strategy.<\/jats:p>","DOI":"10.3390\/curroncol31090368","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:58:46Z","timestamp":1724759926000},"page":"4968-4983","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7625-7708","authenticated-orcid":false,"given":"Elisa","family":"Roca","sequence":"first","affiliation":[{"name":"Thoracic Oncology, Lung Unit, P. Pederzoli Hospital, Peschiera Del Garda, VR, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-5550","authenticated-orcid":false,"given":"Avinash","family":"Aujayeb","sequence":"additional","affiliation":[{"name":"Respiratory Department, Northumbria Health Care NHS Foundation Trust, Care of Gail Hewitt, Newcastle NE23 6NZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-1792","authenticated-orcid":false,"given":"Philippe","family":"Astoul","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, North Hospital, Aix-Marseille University, Chemin des Bourrely, 13005 Marseille, France"},{"name":"La Timone Campus, Aix-Marseille University, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"British Thoracic Society Standards of Care Committee (2007). BTS statement on malignant mesothelioma in the UK. Thorax, 62, ii1\u2013ii19.","DOI":"10.1136\/thx.2007.087619"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ajim.22206","article-title":"Potential years of life lost (PYLL) caused by asbestos-related diseases in the world","volume":"56","author":"Diandini","year":"2013","journal-title":"Am. J. Ind. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2022.03.012","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: Patient-reported outcomes in CheckMate 743","volume":"167","author":"Scherpereel","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"00467-2023","DOI":"10.1183\/23120541.00467-2023","article-title":"Reflecting real-world patients with mesothelioma in research: An interim report of baseline characteristics from the ASSESS-meso cohort","volume":"9","author":"Conway","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/thoraxjnl-2013-203744","article-title":"Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma","volume":"69","author":"Lacourt","year":"2014","journal-title":"Thorax"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","article-title":"Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study","volume":"18","author":"Huang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sahu, R.K., Ruhi, S., Jeppu, A.K., Al-Goshae, H.A., Syed, A., Nagdev, S., Widyowati, R., Ekasari, W., Khan, J., and Bhattacharjee, B. (2023). Malignant mesothelioma tumours: Molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1204722"},{"key":"ref_10","unstructured":"IARC (2012). Evaluation of Carcinogenic Risks to Humans: Arsenic, Metals, Fibers, and Dusts, IARC monographs."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Vorster, T., Mthombeni, J., teWaterNaude, J., and Phillips, J.I. (2022). The Association between the Histological Subtypes of Mesothelioma and Asbestos Exposure Characteristics. Int. J. Environ. Res. Public Heal., 19.","DOI":"10.3390\/ijerph192114520"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jtho.2022.03.012","article-title":"Pulmonary Asbestos Fiber Burden Is Related to Patient Survival in Malignant Pleural Mesothelioma","volume":"17","author":"Laaksonen","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/annweh\/wxae018","article-title":"Lung fibre burden and risk of malignant mesothe-lioma in shipyard workers: A necropsy-based case\u2013control study","volume":"68","author":"Mirabelli","year":"2024","journal-title":"Ann. Work. Expo. Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/2767-9764.CRC-23-0423","article-title":"Low Exposures to Amphibole or Serpentine Asbestos in Germline Bap1-mutant Mice Induce Mesothelioma Characterized by an Immunosuppressive Tumor Microenvironment","volume":"4","author":"Kadariya","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Fiorilla, I., Martinotti, S., Todesco, A.M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., and Audrito, V. (2023). Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma. Cells, 12.","DOI":"10.3390\/cells12162048"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant Mesothelioma and Its Non-Asbestos Causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cam4.656","article-title":"Radiation-induced mesothelioma among long-term solid cancer survivors: A longitudinal analysis of SEER database","volume":"5","author":"Farioli","year":"2016","journal-title":"Cancer Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7249912","DOI":"10.1155\/2022\/7249912","article-title":"Sera from Patients with Malignant Pleural Mesothelioma Tested Positive for IgG Antibodies Against SV40 Large T Antigen: The Viral Oncoprotein","volume":"2022","author":"Mazzoni","year":"2022","journal-title":"J. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.21037\/tlcr.2020.02.03","article-title":"SV40 and human mesothelioma","volume":"9","author":"Carbone","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/gtmb.2023.0532","article-title":"Association Study of Pleural Mesothelioma and Oncogenic Simian Virus 40 in the Cro-cidolite Contaminated Area of Dayao County, Yunnan Province, Southwest China","volume":"28","author":"Liu","year":"2024","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mes-othelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_25","first-page":"1","article-title":"Genetic predisposition for malignant mesothelioma: A concise review","volume":"781","author":"Betti","year":"2019","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes","volume":"57","author":"Betti","year":"2018","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study","volume":"17","author":"Louw","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/thx.52.6.507","article-title":"Malignant Mesothelioma in South East England: Clinicopathological Expe-rience of 272 Cases","volume":"52","author":"Yates","year":"1997","journal-title":"Thorax"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000503239","article-title":"Diagnostic Value of Computed Tomography Imaging Features in Malignant Pleural Mesothelioma","volume":"99","author":"Fortin","year":"2020","journal-title":"Respiration"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.11.010","article-title":"The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy","volume":"103","author":"Tsim","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0720-048X(01)00426-0","article-title":"Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases","volume":"41","author":"Metintas","year":"2002","journal-title":"Eur. J. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccm.2006.02.001","article-title":"Imaging of Pleural Disease","volume":"27","author":"Qureshi","year":"2006","journal-title":"Clin. Chest Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2012.10.017","article-title":"18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography\/Computed Tomography Fused Imaging in Malignant Mesothelioma Patients: Looking from Outside Is Not Enough","volume":"79","author":"Roca","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1159\/000381922","article-title":"Positron Emission Tomography\/Computed Tomography for the Pleural Staging of Ma-lignant Pleural Mesothelioma: How Accurate Is It?","volume":"89","author":"Pinelli","year":"2015","journal-title":"Respiration"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1378\/chest.14-0820","article-title":"Accuracy of Fluorodeoxyglucose-PET Imaging for Differentiating Benign from Malignant Pleural Effusions: A Meta-Analysis","volume":"147","author":"Porcel","year":"2015","journal-title":"Chest"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2018.01.014","article-title":"Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy","volume":"118","author":"Tsim","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1801254","DOI":"10.1183\/13993003.01254-2018","article-title":"Investigating unilateral pleural effusions: The role of cytology","volume":"52","author":"Arnold","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/thorax-2023-220304","article-title":"British Thoracic Society Guideline for pleural disease","volume":"78","author":"Roberts","year":"2023","journal-title":"Thorax"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1753466618808660","DOI":"10.1177\/1753466618808660","article-title":"Biomarkers in the diagnosis of pleural diseases: A 2018 update","volume":"12","author":"Porcel","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/crj.12619","article-title":"Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions","volume":"12","author":"Froudarakis","year":"2017","journal-title":"Clin. Respir. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.chest.2022.11.019","article-title":"Achieving Molecular Profiling in Pleural Biopsies: A Multicenter, Retrospective Cohort Study","volume":"163","author":"Sundaralingam","year":"2023","journal-title":"Chest"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Li, D., Jackson, K., Panchal, R., and Aujayeb, A. (2022). Local Anaesthetic Thoracoscopy for Pleural Effusion\u2014A Narrative Review. Healthcare, 10.","DOI":"10.3390\/healthcare10101978"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1378\/chest.14-0299","article-title":"Physician-Based Ultrasound-Guided Biopsy for Diagnosing Pleural Disease","volume":"146","author":"Hallifax","year":"2014","journal-title":"Chest"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/LBR.0000000000000297","article-title":"Ultrasound-Guided Lung Biopsy in the Hands of Respiratory Physicians: Diag-nostic Yield and Complications in 215 Consecutive Patients in 3 Centers","volume":"23","author":"Laursen","year":"2016","journal-title":"J. Bronchol. Interv. Pulmonol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.acra.2013.09.015","article-title":"Diagnostic Accuracy of 18F-FDG-PET and PET\/CT in the Differential Diagnosis between Malignant and Benign Pleural Lesions: A Systematic Review and Meta-Analysis","volume":"21","author":"Treglia","year":"2014","journal-title":"Acad. Radiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2301295","DOI":"10.1183\/13993003.01295-2023","article-title":"PET-CT-Guided versus CT-Guided Biopsy in Suspected Malignant Pleural Thickening: A Randomised Trial","volume":"63","author":"Arnold","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1827.2010.02534.x","article-title":"9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis","volume":"60","author":"Takeda","year":"2010","journal-title":"Pathol. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jso.21901","article-title":"Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations","volume":"104","author":"Rena","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted Epidermal Growth Factor Receptor Therapy in Malignant Pleural Mesothelioma: Where Do We Stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: Functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/mi.2014.129","article-title":"The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung","volume":"8","author":"Fujimori","year":"2015","journal-title":"Mucosal Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/LCTT.S288535","article-title":"An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma","volume":"13","author":"Davis","year":"2022","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_60","first-page":"1","article-title":"The Hippo signalling pathway and its implications in human health and diseases","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"dev196675","DOI":"10.1242\/dev.196675","article-title":"TEAD family transcription factors in development and disease","volume":"148","author":"Currey","year":"2021","journal-title":"Development"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo Pathway: Biology and Pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13073-021-00931-w","article-title":"Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma","volume":"13","author":"Meiller","year":"2021","journal-title":"Genome Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7","article-title":"Merlin differentially associates with the microtubule and actin cytoskeleton","volume":"51","author":"Xu","year":"1998","journal-title":"J. Neurosci. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1440-1827.2011.02666.x","article-title":"Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation","volume":"61","author":"Sekido","year":"2011","journal-title":"Pathol. Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.bjc.6604002","article-title":"Nf2\/Merlin: A Coordinator of Receptor Signalling and Intercellular Contact","volume":"98","author":"Curto","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sekido, Y. (2018). NF2\/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19040988"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"Montero","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjc.6600681","article-title":"Arginine Deprivation, Growth Inhibition and Tumour Cell Death: Enzymatic Deg-radation of Arginine in Normal and Malignant Cell Cultures","volume":"88","author":"Philip","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sharma, S., Agnihotri, N., and Kumar, S. (2022). Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis. Biochem. Pharmacol., 198.","DOI":"10.1016\/j.bcp.2022.114943"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin Is Not Required for Normal Mouse Development or Reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Melaiu, O., Stebbing, J., Lombardo, Y., Bracci, E., Uehara, N., Bonotti, A., Cristaudo, A., Foddis, R., Mutti, L., and Barale, R. (2014). MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085935"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A Binding Domain on Mesothelin for CA125\/MUC1","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"CT007","DOI":"10.1158\/1538-7445.AM2023-CT007","article-title":"Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma","volume":"83","author":"Szlosarek","year":"2023","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_79","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_81","first-page":"1741","article-title":"Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer","volume":"19","author":"Inoue","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1373\/jalm.2017.025015","article-title":"Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer","volume":"3","author":"Yu","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment","volume":"179","author":"Grigoriu","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2018.03.032","article-title":"Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation","volume":"425","author":"Chen","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1 Associated Protein 1 Interferes with BRCA1\/BARD1 RING Heterodimer Ac-tivity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: A novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"102101","DOI":"10.1016\/j.ctrv.2020.102101","article-title":"Is DNA Repair a Potential Target for Effective Therapies against Malignant Mesothelioma?","volume":"90","author":"Roca","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41416-021-01547-y","article-title":"Efficacy of CDK4\/6 Inhibitors in Preclinical Models of Malignant Pleural Mesothelioma","volume":"125","author":"Aliagas","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e004145","DOI":"10.1136\/bmjopen-2013-004145","article-title":"Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: Updated meta-analysis","volume":"4","author":"Cui","year":"2014","journal-title":"BMJ Open"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/bjc.2015.62","article-title":"The South West Area Mesothelioma and Pemetrexed trial: A multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication","volume":"112","author":"Hooper","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9532","DOI":"10.1200\/jco.2005.23.16_suppl.9532","article-title":"Soluble mesothelin related peptides: A potential biomarker for malignant pleural mesothelioma","volume":"23","author":"Pass","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1055-9965.EPI-20-0083","article-title":"Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network","volume":"29","author":"Pass","year":"2020","journal-title":"Cancer Epidemiology Biomarkers Prev."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sorino, C., Mondoni, M., Marchetti, G., Agati, S., Inchingolo, R., Mei, F., Flamini, S., Lococo, F., and Feller-Kopman, D. (2023). Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers. J. Clin. Med., 12.","DOI":"10.3390\/jcm12227006"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1700919","DOI":"10.1183\/13993003.00919-2017","article-title":"Exhaled breath to screen for malignant pleural mesothelioma: A validation study","volume":"50","author":"Lamote","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"047105","DOI":"10.1088\/1752-7163\/acf7e3","article-title":"Determining the Clinical Utility of a Breath Test for Screening an Asbes-tos-Exposed Population for Pleural Mesothelioma: Baseline Results","volume":"17","author":"Zwijsen","year":"2023","journal-title":"J. Breath. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum Mesothelin and Other Biomarkers: What Have We Learned in the Last Decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: A systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels","volume":"353","author":"Pass","year":"2005","journal-title":"New Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage, and Changes in Tumor Burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma","volume":"28","author":"Yang","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma","volume":"6","author":"Cristaudo","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2014.02.024","article-title":"Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: A systematic review and meta-analysis","volume":"433","author":"Hu","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Tabata, C., Shibata, E., Tabata, R., Kanemura, S., Mikami, K., Nogi, Y., Masachika, E., Nishizaki, T., and Nakano, T. (2013). Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-205"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/bjc.2015.470","article-title":"A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma","volume":"114","author":"Kao","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Nowak, A.K., Brosseau, S., Cook, A., and Zalcman, G. (2020). Antiangiogeneic Strategies in Mesothelioma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00126"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"O\u2018Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Russo, G.L., Tessari, A., Capece, M., Galli, G., de Braud, F., Garassino, M.C., and Palmieri, D. (2018). MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00650"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Sriram, K.B., Relan, V., Clarke, B.E., Duhig, E.E., Windsor, M.N., Matar, K.S., Naidoo, R., Passmore, L., McCaul, E., and Courtney, D. (2012). Pleural Fluid Cell-Free DNA Integrity Index to Identify Cytologically Negative Ma-lignant Pleural Effusions Including Mesotheliomas. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-428"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2018.07.028","article-title":"Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients","volume":"124","author":"Hylebos","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/cas.13895","article-title":"Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma","volume":"110","author":"Yoneda","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Duong, B.T.V., Wu, L., Green, B.J., Bavaghar-Zaeimi, F., Wang, Z., Labib, M., Zhou, Y., Cantu, F.J.P., Jeganathan, T., and Popescu, S. (2020). A Liquid Biopsy for Detecting Circulating Mesothelial Precursor Cells: A New Bi-omarker for Diagnosis and Prognosis in Mesothelioma. EBioMedicine, 61.","DOI":"10.1016\/j.ebiom.2020.103031"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"102949","DOI":"10.1016\/j.critrevonc.2020.102949","article-title":"Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review","volume":"150","author":"Ahmadzada","year":"2020","journal-title":"Crit. Rev. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Faversani, A., Favero, C., Dioni, L., Pesatori, A.C., Bollati, V., Montoli, M., Musso, V., Terrasi, A., Fusco, N., and Nosotti, M. (2021). An EBC\/Plasma miRNA Signature Discriminates Lung Adenocarcinomas From Pleural Mesothelioma and Healthy Controls. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.643280"},{"key":"ref_129","first-page":"2198","article-title":"Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis","volume":"44","author":"Jotatsu","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"The MoMar Study Group, Weber, D.G., Casjens, S., Brik, A., Raiko, I., Lehnert, M., Taeger, D., Gleichenhagen, J., Kollmeier, J., and Bauer, T.T. (2020). Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies. Biomark. Res., 8, 15.","DOI":"10.1186\/s40364-020-00194-4"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-019-0078-1","article-title":"Artificial intelligence for precision oncology: Beyond patient stratification","volume":"3","author":"Azuaje","year":"2019","journal-title":"npj Precis. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Cavallari, I., Urso, L., Sharova, E., Pasello, G., and Ciminale, V. (2019). Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00740"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"434","DOI":"10.37349\/etat.2020.00028","article-title":"Circulating biomarkers in malignant pleural mesothelioma","volume":"1","author":"Viscardi","year":"2020","journal-title":"Explor. Target. Anti-tumor Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/comjnl\/bxab015","article-title":"A Machine Learning Approach for Identification of Malignant Mesothelioma Etiological Factors in an Imbalanced Dataset","volume":"65","author":"Alam","year":"2021","journal-title":"Comput. J."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Latif, M.Z., Shaukat, K., Luo, S., Hameed, I.A., Iqbal, F., and Alam, T.M. (2020, January 12\u201313). Risk Factors Identification of Malignant Mesothelioma: A Data Mining Based Approach. Proceedings of the 2020 International Conference on Electrical, Communication, and Computer Engineering (ICECCE), Istanbul, Turkey.","DOI":"10.1109\/ICECCE49384.2020.9179443"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/THC-202237","article-title":"Predicting cancer using supervised machine learning: Mesothelioma","volume":"29","author":"Choudhury","year":"2021","journal-title":"Technol. Health Care"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Alam, T.M., Shaukat, K., Hameed, I.A., Khan, W.A., Sarwar, M.U., Iqbal, F., and Luo, S. (2021). A novel framework for prognostic factors identification of malignant mesothelioma through association rule mining. Biomed. Signal Process. Control., 68.","DOI":"10.1016\/j.bspc.2021.102726"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2018182","DOI":"10.1080\/08839514.2021.2018182","article-title":"A Novel Multi-Neural Ensemble Approach for Cancer Diagnosis","volume":"36","author":"Gupta","year":"2022","journal-title":"Appl. Artif. Intell."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T De-scriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","article-title":"The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation","volume":"11","author":"Pass","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma","volume":"11","author":"Krug","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jtcvs.2004.10.034","article-title":"Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications","volume":"129","author":"Erasmus","year":"2005","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000356752","article-title":"Positive FDG-PET\/CT of the Pleura Twenty Years after Talc Pleurodesis: Three Cases of Benign Talcoma","volume":"87","author":"Vandemoortele","year":"2014","journal-title":"Respiration"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1510\/icvts.2010.255893","article-title":"What Is the Best Way to Diagnose and Stage Malignant Pleural Mesothelioma?","volume":"12","author":"Zahid","year":"2011","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lungcan.2016.01.017","article-title":"Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET\/CT in local thoracic staging of malignant pleural mesothelioma","volume":"94","author":"Martini","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"W125","DOI":"10.2214\/AJR.09.3519","article-title":"Diffusion-Weighted MRI of Malignant Pleural Mesothelioma: Preliminary Assessment of Apparent Diffusion Coefficient in Histologic Subtypes","volume":"195","author":"Gill","year":"2010","journal-title":"Am. J. Roentgenol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejcts.2008.03.034","article-title":"Video-assisted cervical thoracoscopy: A novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma","volume":"34","author":"Chamberlain","year":"2008","journal-title":"Eur. J. Cardio-Thoracic Surg."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/SLA.0000000000000903","article-title":"Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma","volume":"260","author":"Sugarbaker","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.athoracsur.2009.05.022","article-title":"Endoscopic Ultrasound-Guided Fine Needle Aspiration for Staging of Malignant Pleural Mesothelioma","volume":"88","author":"Rice","year":"2009","journal-title":"Ann. Thorac. Surg."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ejcts\/ezr251","article-title":"The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma","volume":"42","author":"Nakas","year":"2012","journal-title":"Eur. J. Cardio-Thoracic Surg."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1510\/icvts.2009.213611","article-title":"Staging algorithm for diffuse malignant pleural mesothelioma","volume":"10","author":"Hauer","year":"2010","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1445-2197.2009.05060.x","article-title":"Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy","volume":"79","author":"Alvarez","year":"2009","journal-title":"ANZ J. Surg."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification","volume":"11","author":"Churg","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0003-9969(77)90111-X","article-title":"Effects of X-irradiation and the resultant inanition on amylase content of the rat parotid gland","volume":"22","author":"Sodicoff","year":"1977","journal-title":"Arch. Oral Biol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.21037\/tlcr-20-592","article-title":"Rethought histologic classification of pleural mesothelioma to better treat: Go forward from looking back","volume":"9","author":"Astoul","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Travis, W.D., Brambilla, E., Burke, A.P., and Nicholson, A.G. (2015). Tumours of the Pleura. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, International Agency for Research on Cancer.","DOI":"10.1097\/JTO.0000000000000663"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1378\/chest.120.6.1798","article-title":"Percutaneous Image-Guided Cutting Needle Biopsy of the Pleura in the Diagnosis of Malignant Mesothelioma","volume":"120","author":"Adams","year":"2001","journal-title":"Chest"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/his.13468","article-title":"Malignant Mesothelioma in Situ","volume":"72","author":"Churg","year":"2018","journal-title":"Histopathology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Mastromarino, M.G., Lenzini, A., Aprile, V., Al\u00ec, G., Bacchin, D., Korasidis, S., Ambrogi, M.C., and Lucchi, M. (2022). New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications. Diagnostics, 12.","DOI":"10.3390\/diagnostics12122905"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","volume":"15","author":"Nicholson","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"747","DOI":"10.5858\/arpa.2017-0295-OA","article-title":"Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping","volume":"142","author":"Brcic","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jtho.2018.07.002","article-title":"Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal","volume":"13","author":"Pelosi","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: A multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0000000000001416","article-title":"Utility of Nuclear Grading System in Epithelioid Malignant Pleural Meso-thelioma in Biopsy-Heavy Setting: An External Validation Study of 563 Cases","volume":"44","author":"Zhang","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/00000478-200110000-00012","article-title":"Well-Differentiated Papillary Mesothelioma","volume":"25","author":"Butnor","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: Morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00428-019-02674-x","article-title":"Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: A case report","volume":"476","author":"Minami","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:43:25Z","timestamp":1760111005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":172,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090368"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090368","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}